Double 5-fluorouracil modulation with folinic acid and recombinant alpha- 2B-interferon: A Phase I-II study in metastatic colorectal cancer patients

I. Brunetti, A. Falcone, M. Bertuccelli, C. Cianci, S. Ricci, P. F. Conte

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-two patients with metastatic colorectal cancer entered a Phase I- II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination. Diarrhea and mucositis were the most frequent 5- fluorouracil-related toxicities and were ≥ECOG grade 3 in 23% and 18% of patients, respectively. Of 15 patients receiving interferon ≥9 x 106 IU, 10 required interferon dose reduction mostly because of severe fatigue, anorexia, and declining performance status. Among 19 patients evaluable for response, 3 achieved a partial response and 1 a complete response for an overall response rate of 21% (95% confidence interval, 6-46%). In conclusion, our study demonstrates that IFN-α2B at doses higher than 6 x 106 IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5- fluorouracil plus folinic acid without IFN-α. A larger Phase III study would be required to determine the value of IFN-α in this combination.

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number3
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Double 5-fluorouracil modulation with folinic acid and recombinant alpha- 2B-interferon: A Phase I-II study in metastatic colorectal cancer patients'. Together they form a unique fingerprint.

Cite this